Votrient (Pazopanib HCl) Patent Expiration, LOE Window & CMS Spending

Votrient (Pazopanib HCl) by Novartis: Off-Patent Genericized (AB Competition), 5 AB generics, $32.9M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN022465 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$32.9M
2024 Medicare Part D Spend$22.2M
2024 Medicaid Spend$10.7M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 16.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.